Patents by Inventor Jan A. Nolta

Jan A. Nolta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220002748
    Abstract: This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.
    Type: Application
    Filed: February 5, 2021
    Publication date: January 6, 2022
    Inventors: Jan Nolta, Karen Pepper, Fernando Fierro, Gerhard Bauer
  • Patent number: 10913957
    Abstract: This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: February 9, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jan Nolta, Karen Pepper, Fernando Fierro, Gerhard Bauer
  • Publication number: 20200113943
    Abstract: This disclosure relates to populations and compositions of purified cell-derived vesicles and uses thereof. One aspect of the disclosure relates to methods for purifying the cell-derived vesicles.
    Type: Application
    Filed: June 5, 2018
    Publication date: April 16, 2020
    Inventors: Johnathon D. ANDERSON, Jan A. NOLTA, Gerhard BAUER, Brian FURY
  • Publication number: 20190276843
    Abstract: This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.
    Type: Application
    Filed: October 5, 2018
    Publication date: September 12, 2019
    Inventors: Jan Nolta, Karen Pepper, Fernando Fierro, Gerhard Bauer
  • Publication number: 20190008902
    Abstract: This disclosure relates to populations and compositions of purified cell-derived vesicles and uses thereof. One aspect of the disclosure relates to methods for purifying the cell-derived vesicles.
    Type: Application
    Filed: December 30, 2016
    Publication date: January 10, 2019
    Inventors: Johnathon D. ANDERSON, Jan A. NOLTA, Gerhard BAUER, Brian FURY
  • Publication number: 20180022787
    Abstract: This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.
    Type: Application
    Filed: May 29, 2017
    Publication date: January 25, 2018
    Inventors: Jan Nolta, Karen Pepper, Fernando Fierro, Gerhard Bauer
  • Publication number: 20170314042
    Abstract: This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.
    Type: Application
    Filed: November 14, 2016
    Publication date: November 2, 2017
    Applicant: The Regents of the University of California
    Inventors: Jan Nolta, Karen Pepper, Fernando Fierro, Gerhard Bauer
  • Patent number: 9663564
    Abstract: This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 30, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jan Nolta, Karen Pepper, Fernando Fierro, Gerhard Bauer
  • Publication number: 20170000886
    Abstract: An isolated polynucleotide comprising the element of: a promoter element that drives expression of the C—C motif ligand 5 (“a CCL5 promoter”) operatively linked to a polynucleotide encoding a fusion polypeptide comprising the Fc and hinge regions of a human IgG CD44 variant 6 (CD44v6) polypeptide is described.
    Type: Application
    Filed: June 22, 2016
    Publication date: January 5, 2017
    Inventors: Astra Chang, Jan Nolta
  • Publication number: 20160263160
    Abstract: Compositions and methods for delivering a siRNA, dsRNA, or miRNA polynucleotide into a target cell comprising contacting the target cell with a mesenchymal stem cell, which mesenchymal stem cell comprises an exogenous DNA sequence expressing the siRNA or dsRNA polynucleotide, thereby delivering the siRNA, dsRNA, or miRNA polynucleotide to the target cell through a cellular protrusion or a microvesicle.
    Type: Application
    Filed: May 23, 2016
    Publication date: September 15, 2016
    Inventors: Jan A. Nolta, Scott Olson, Louisa Wirthlin
  • Publication number: 20160046685
    Abstract: This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 18, 2016
    Inventors: Jan Nolta, Karen Pepper, Fernando Fierro, Gerhard Bauer
  • Publication number: 20140309289
    Abstract: Recombinant lentiviral vectors containing at least: a lentiviral backbone comprising essential lentiviral sequences for integration into a target cell genome; a nucleic acid encoding a CCR5 RNAi; and an expression control element that regulates expression of the nucleic acid encoding the CCR5 RNAi element, are provided by this invention. In an alternative aspect, the vector also contains polynucleotides encoding TRIM5 alpha and HIV TAR decoy sequences along with gene expression regulation elements such as promoters operatively linked to the polynucleotides. The vectors are combined with packaging plasmid and envelope plasmids and optionally conjugated to cell-specific targeting antibodies. Diagnostic and therapeutic methods for using the compositions are further provided herein.
    Type: Application
    Filed: April 16, 2014
    Publication date: October 16, 2014
    Applicant: The Regents of the University of California
    Inventors: Joseph Anderson, Gerhard Bauer, Jan A. Nolta
  • Patent number: 8728458
    Abstract: Recombinant lentiviral vectors containing at least: a lentiviral backbone comprising essential lentiviral sequences for integration into a target cell genome; a nucleic acid encoding a CCR5 RNAi; and an expression control element that regulates expression of the nucleic acid encoding the CCR5 RNAi element, are provided by this invention. In an alternative aspect, the vector also contains polynucleotides encoding TRIM5 alpha and HIV TAR decoy sequences along with gene expression regulation elements such as promoters operatively linked to the polynucleotides. The vectors are combined with packaging plasmid and envelope plasmids and optionally conjugated to cell-specific targeting antibodies. Diagnostic and therapeutic methods for using the compositions are further provided herein.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: May 20, 2014
    Assignee: The Regents of the University of California
    Inventors: Joseph Anderson, Gerhard Bauer, Jan A. Nolta
  • Publication number: 20140065110
    Abstract: This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 6, 2014
    Applicant: The Regents of the University of California
    Inventors: Jan Nolta, Karen Pepper, Fernando Fierro, Gerhard Bauer
  • Publication number: 20140023624
    Abstract: This disclosure provides an isolated or purified decellularized liver extracellular matrix (DLM) composition containing an isolated or purified cell capable of differentiating into a hepatocyte and/or liver tissue, and methods for its use in vitro and in vivo.
    Type: Application
    Filed: December 30, 2011
    Publication date: January 23, 2014
    Inventors: Ping Zhou, Jian Wu, Jan Nolta
  • Publication number: 20120114618
    Abstract: Compositions and methods for delivering a siRNA, dsRNA, or miRNA polynucleotide into a target cell comprising contacting the target cell with a mesenchymal stem cell, which mesenchymal stem cell comprises an exogenous DNA sequence expressing the siRNA or dsRNA polynucleotide, thereby delivering the siRNA, dsRNA, or miRNA polynucleotide to the target cell through a cellular protrusion or a microvesicle.
    Type: Application
    Filed: March 25, 2010
    Publication date: May 10, 2012
    Inventors: Jan A. Nolta, Scott Olson, Louisa Wirthlin
  • Publication number: 20120076763
    Abstract: Recombinant lentiviral vectors containing at least: a lentiviral backbone comprising essential lentiviral sequences for integration into a target cell genome; a nucleic acid encoding a CCR5 RNAi; and an expression control element that regulates expression of the nucleic acid encoding the CCR5 RNAi element, are provided by this invention. In an alternative aspect, the vector also contains polynucleotides encoding TRIMS alpha and HIV TAR decoy sequences along with gene expression regulation elements such as promoters operatively linked to the polynucleotides. The vectors are combined with packaging plasmid and envelope plasmids and optionally conjugated to cell-specific targeting antibodies. Diagnostic and therapeutic methods for using the compositions are further provided herein.
    Type: Application
    Filed: April 29, 2010
    Publication date: March 29, 2012
    Inventors: Joseph Anderson, Gerhard Bauer, Jan A. Nolta